Treatment Refractory MAC Lung Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Treatment refractory MAC lung disease is a lung infection that does not get better with usual treatments. UCSF is running a study to test if an inhaled medicine called Clofazimine can help. This study looks at how safe and effective this new treatment is for patients.

Showing trials for

  • ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment with MNKD-101, Clofazimine Inhalation Suspension

    open to eligible people ages 18-85

    This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

    Fresno, California and other locations

  • Epetraborole in Patients With Treatment-refractory MAC Lung Disease

    Sorry, in progress, not accepting new patients

    This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

    San Francisco, California and other locations

Last updated: